Scopul nostru este sprijinirea şi promovarea cercetării ştiinţifice şi facilitarea comunicării între cercetătorii români din întreaga lume.
Autori: M. Puiu, S. Arghirescu, M. Bataneant, R. Firescu, L. Stana, M. Baica, M. Mihailov,M. Serban;
Editorial: nature publishing group, European journal of human genetics, Volume 15 Supplement 1 June 2007, p.161, 2007.
Background. Acute lymphoblastic leukemia (ALL) refers to a group of heterogeneous diseases with different clinical expression and prognosis. Therefore, patients require precise and complete initial evaluation of risk factors including cytogenetics, immunophenotype and biomolecular assessment in order to plan an individualised, optimal treatment regimen.
Objectives. We aimed at evaluating the biological profile of leukemic cells and its particularities in ALL.
Patients and methods. We analyzed cytogenetics, cell surface markers and biomolecular parameters in connection with clinical parameters (sex, age, risk factors, ethnic group, central nervous system leukemia, mediastinal mass) in 156 ALL patients aged 0-18 years, treated in our Clinic between 1990-2002.
Results. Compared to data from literature, in our study group we noticed no differences between sex distribution (56% vs. 57% being males), a lower proportion of patients belonging to 2-6 years age group (53.8% vs. 77%) and a double proportion of patients older than 6 years (41.6% vs. 20%). Frequency of medium and high risk forms was higher in study group (75.6% and 10.2% vs. 59.46% and 10.65%) and also the incidence of L3-ALL (3.3%). Biomolecular assessment revealed a comparable proportion of patients with t(9,22)-BCR-ABL mutation (1.28%) and a higher proportion of t(14,11) MLL-AF4 (2.56%). Leukemic cells expressed lymphoid CD10 marker in 35.07% vs. 63.01%. There were no differences between central nervous system involvement in newly diagnosed ALL (3.8% vs. 4%). These data can explain the worse prognosis of our patients.
Conclusions. Our results provide practical information that should be taken into account for planning individualized treatment.
Cuvinte cheie: leucemie, imunofenotip, citogenetica // leukemia, immunophenotype, cytogenetics